The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Endocrinology Research Centre
2019-09-01
|
| Saila: | Ожирение и метаболизм |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.omet-endojournals.ru/jour/article/view/10243 |